85 related articles for article (PubMed ID: 3734845)
1. Does maintenance therapy with alpha interferon stabilize cancer growth? A pilot study.
Laszlo J; Goldstein D; Vugrin D; Hood L; Tso CY
J Biol Response Mod; 1986 Aug; 5(4):294-9. PubMed ID: 3734845
[TBL] [Abstract][Full Text] [Related]
2. Recombinant interferon alpha-2 (INTRON A) in a phase II study of renal cell carcinoma.
Kempf RA; Grunberg SM; Daniels JR; Skinner DG; Venturi CL; Spiegel R; Neri R; Greiner JM; Rudnick S; Mitchell MS
J Biol Response Mod; 1986 Feb; 5(1):27-35. PubMed ID: 3958753
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F
Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987
[TBL] [Abstract][Full Text] [Related]
4. [A cooperative phase I-II study of HLBI in patients with malignant tumors].
Kimura K
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1324-31. PubMed ID: 6329104
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of lymphoblastoid interferon in metastatic colon carcinoma.
Chaplinski T; Laszlo J; Moore J; Silverman P
Cancer Treat Rep; 1983 Nov; 67(11):1009-12. PubMed ID: 6640552
[TBL] [Abstract][Full Text] [Related]
6. High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study.
Trump DL; Elson PJ; Borden EC; Harris JE; Tuttle RL; Whisnant JK; Oken MM; Carignan JR; Ruckdeschel JC; Davis TE
Cancer Treat Rep; 1987 Feb; 71(2):165-9. PubMed ID: 3802113
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of alpha-lymphoblastoid interferon given weekly as treatment of advanced breast cancer.
Sarna GP; Figlin RA
Cancer Treat Rep; 1985 May; 69(5):547-9. PubMed ID: 4005877
[TBL] [Abstract][Full Text] [Related]
8. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial.
Kirkwood JM; Harris JE; Vera R; Sandler S; Fischer DS; Khandekar J; Ernstoff MS; Gordon L; Lutes R; Bonomi P
Cancer Res; 1985 Feb; 45(2):863-71. PubMed ID: 3881175
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of weekly high-dose human lymphoblastoid interferon.
Connors JM; Silver HK
Cancer Treat Rep; 1984 Sep; 68(9):1093-6. PubMed ID: 6478449
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of human lymphoblastoid interferon in patients with multiple myeloma.
Cox EB; Laszlo J; Krown S; Mintzer D; Sarna G
J Biol Response Mod; 1988 Jun; 7(3):318-25. PubMed ID: 3392554
[TBL] [Abstract][Full Text] [Related]
11. [Phase-1 study of the tolerance for increasing doses of recombinant human alpha 2 interferon in patients with advanced cancer].
Bretaudeau B; Palangie T; Giralt E; Jouve M; Pouillart P; Falcoff E; Fridman WH; Magdelenat H; Derstepani L; Laurent T
Bull Cancer; 1984; 71(1):40-9. PubMed ID: 6713113
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of high-dose human lymphoblastoid alpha interferon in patients with advanced renal carcinoma.
Vugrin D; Hood L; Laszlo J
J Biol Response Mod; 1986 Aug; 5(4):309-12. PubMed ID: 3734846
[TBL] [Abstract][Full Text] [Related]
13. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of alpha (human leukocyte) interferon administered daily in adenocarcinoma of the colon/rectum.
Figlin RA; Callaghan M; Sarna G
Cancer Treat Rep; 1983 May; 67(5):493-4. PubMed ID: 6850664
[TBL] [Abstract][Full Text] [Related]
15. [Clinical trial of human lymphoblastoid interferon on advanced malignancy].
Usui N; Ogawa M; Inagaki J; Horikoshi N; Inoue K; Miyamoto H; Ikeda K; Nakada H; Adachi K; Okada Y
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2324-9. PubMed ID: 6357102
[TBL] [Abstract][Full Text] [Related]
16. Interferon-alpha therapy of renal cancer.
Neidhart JA; Gagen MM; Young D; Tuttle R; Melink TJ; Ziccarrelli A; Kisner D
Cancer Res; 1984 Sep; 44(9):4140-3. PubMed ID: 6378379
[TBL] [Abstract][Full Text] [Related]
17. Phase I evaluation of a synthetic mutant of beta-interferon.
Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
[TBL] [Abstract][Full Text] [Related]
18. Clinical investigation of partially pure and recombinant DNA derived leukocyte interferon in human cancer.
Gutterman J; Quesada J
Tex Rep Biol Med; 1981-1982; 41():626-33. PubMed ID: 6763369
[No Abstract] [Full Text] [Related]
19. Open-label phase II trial of recombinant beta interferon (IFN-beta (ser)) in patients with colorectal cancer.
Triozzi PL; Kenney P; Young D; Rinehart JJ
Cancer Treat Rep; 1987 Oct; 71(10):983-4. PubMed ID: 3308083
[No Abstract] [Full Text] [Related]
20. [Histopathologic evaluation of anti-tumor activity of alpha-interferon for renal cell carcinoma, especially in autoptic cases].
Yamauchi T; Kawamura J; Yoshida O; Fukuyama T; Ogura K; Nakagawa K
Hinyokika Kiyo; 1985 Sep; 31(9):1539-52. PubMed ID: 4083212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
